期刊文献+

某传染病院的医院感染现患率调查分析 被引量:1

原文传递
导出
摘要 目的了解某传染病院的医院感染状况,发现医院感染规律,为控制医院感染提供依据。方法按照2018年全国医院感染横断面调查计划书要求,对2018年8月15日0点至24点在院所有住院病人发生医院感染情况进行调查分析。结果本次共调查309人,实查率100%,医院感染发生率2.9%(9/309),低于国家要求的8%;感染部位以下呼吸道感染居多(55.6%,5/9);感染病例主要在内科系统(66.6%,6/9);抗菌药物使用率48.2%(149/309),其中治疗用药占79.9%(119/149);≥二联抗菌药物使用率45.0%(67/149);病原学送检率为39.6%(59/149)。结论该院的医院感染发生率低,但抗菌药物的使用仍需规范,同时应提高病原体送检率。应加强对医务人员抗菌药物与院感控制的强化培训。
作者 陈美 姜坤
出处 《海峡预防医学杂志》 CAS 2020年第1期107-108,共2页 Strait Journal of Preventive Medicine
  • 相关文献

参考文献4

二级参考文献29

  • 1李少林,王荣福.核医学[M].7版.北京:人民卫生出版社,2008:88.
  • 2Cooper DS, Doherty GM, Haugen BR, et al. Management guide- lines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2006, 16(2): 109-142.
  • 3Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thy- roid nodules and differentiated thyroid cancer[ J ]. Thyroid, 2009, 19(11): 1167 -1214.
  • 4Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioac- tive iodine remnant ablation : using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system[ J]. Thyroid, 2010, 20(12) : 1341 - 1349.
  • 5Vetter RJ. Regulations for radioiodine therapy in the United States: current status and the process of change [ J]. Thyroid, 1997, 7(2) : 209 -211.
  • 6Ross DS, Ridgway EC, Daniels GH. Successful treatment of soli- tary toxic thyroid nodules with relatively low - dose iodine - 131, with low prevalence of hypothyroidism [ J ]. Ann Intern Med, 1984, 101(4) : 488 -490.
  • 7Watanabe H. Explanation of the draft, "release of patients after therapy with unsealed radionuclides" of the International Commis- sion on Radiological Protection: the 2nd report[ J]. Nihon Hosha- sen Gijatsu Gakkai Zasshi, 2004, 60(5): 689-697.
  • 8Kusakabe K, Yokoyama K, ho K, et al. Thyroid remnant ablation using 1, 110 MBq of I - 131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine the- rapy[J]. Ann Nucl Med, 2012, 26(4) : 370 -378.
  • 9Willegaignon J, Malvestiti LF, Guimaraes MI, et al. 1311 effective half- life (Teff) for patients with thyroid cancer [ J]. Health Phys, 2006, 91(2): 119-122.
  • 10Remy H, Borget I, Leboulleux S, et al. 131I effective half- life and dosimetry in thyroid cancer patients [ J ]. J Nucl Med, 2008, 49(9) : 1445 -1450.

共引文献44

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部